Difference between revisions of "Luspatercept (Reblozyl)"
Jump to navigation
Jump to search
m (→Also known as) |
m |
||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| + | *4/3/2020: Initial FDA approval for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk [[Myelodysplastic syndrome|myelodysplastic syndromes with ring sideroblasts (MDS-RS)]] or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). | ||
==Also known as== | ==Also known as== | ||
Revision as of 19:52, 29 November 2020
Mechanism of action
From the NCI Drug Dictionary: A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, luspatercept inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. Luspatercept acts at a different, later stage than erythropoietin.
Diseases for which it is used
History of changes in FDA indication
- 4/3/2020: Initial FDA approval for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
Also known as
- Code name: ACE-536
- Generic name: luspatercept-aamt
- Brand name: Reblozyl